Patents by Inventor Peter Blurton

Peter Blurton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20100204230
    Abstract: Compounds of formula (I) selectively inhibit production of A?(1-42) and hence find use in treatment of Alzheimer's disease and other conditions associated with deposition of A(?) in the brain.
    Type: Application
    Filed: February 11, 2008
    Publication date: August 12, 2010
    Inventors: Peter Blurton, Stephen Fletcher, Martin Teall, Timothy Harrison, Benito Munoz, Alexey Rivkin, Christopher Hamblett, Phieng Siliphaivanh, Karin Otte
  • Publication number: 20100093748
    Abstract: The invention provides PKA and PKB kinase-inhibiting compounds of the formula (I): or salts, solvates, tautomers or N-oxides thereof, wherein E is a five membered heteroaryl ring containing 1, 2, 3 or 4 heteroatoms selected from O, N and S provided that no more than 1 heteroatom may be other than N; q and r are each is 0 or 1; provided that q+r is 1 or 2; T is N or a group CR5; J1-J2 is N?C(R6), (R7)C?N, (R8)N—C(O), (R8)2C—C(O), N?N or (R7)C?C(R6); Q3 is a bond or a saturated C1-3 hydrocarbon linker group optionally substituted by fluorine and hydroxy; G is NR2R3, CN or OH; m and n are each 0 or 1, provided that m+n is 1 or 2, and provided also that m or n are each 0 when the adjacent ring member of ring E is S or O; R1a and R1b are the same or different and each is hydrogen or a substituent R10; or R1a and R1b together with the carbon atoms or heteroatoms to which they are attached form a 5 or 6-membered aryl or heteroaryl ring, wherein the aryl or heteroaryl rings are optionally substituted by one or mo
    Type: Application
    Filed: December 21, 2007
    Publication date: April 15, 2010
    Applicants: ASTEX THERAPEUTICS LIMITED, THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOS, Cancer Research Technology Limited
    Inventors: Steven John Woodhead, Martyn Frederickson, Christopher Hamlett, Andrew James Woodhead, Marinus Leendert Verdonk, Hannah Fiona Sore, David Winter Walker, Peter Blurton, Ian Collins, Kwai Ming Cheung, John Caldwell, Tatiana Faria Da Fonseca McHardy, Richard William Arthur Luke, Zbigniew Stanley Matusiak, Andrew Leach, Jeffrey James Morris
  • Publication number: 20080300261
    Abstract: Compounds of formula I are useful in treatment of diseases associated with the deposition of ?-amyloid in the brain.
    Type: Application
    Filed: July 19, 2005
    Publication date: December 4, 2008
    Inventors: Peter Blurton, Frank Burkamp, Ian Churcher, Timothy Harrison, Joseph Neduvelil
  • Patent number: 7442701
    Abstract: The present invention provides a compound of formula (I): wherein V represents NR5, O, S, SO or S(O)2; W and X each independently represent CH or N; Y represents N, CH or C—Ar2, with the proviso that at least one, but no more than two, of W, X and Y are N; Z represents CH or C—Ar2, with the proviso that when Y is N or CH then Z is C—Ar2, and with the further proviso that when Y is C—Ar2 then Z is CH; Ar1 represents a fused 9 or 10 membered heterobicyclic ring system containing one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur, wherein at least one of the rings in said ring system is aromatic; Ar2 represents an aromatic ring selected from phenyl, pyridyl, pyrimidinyl and pyridazinyl which is optionally fused and substituted; R1 represents halogen, hydroxy, oxo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkoxy, C3-7cycloalkyl, C3-7cycloalkoxy, C3-5cycloalkylC1-4alkyl, cyano, nitro, SR6, SOR6, SO2R6, COR6, NR3COR6, CON
    Type: Grant
    Filed: November 14, 2003
    Date of Patent: October 28, 2008
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Peter Blurton, Frank Burkamp, Stephen Robert Fletcher, Gregory John Hollingworth, A. Brian Jones, Edward Giles McIver, Christopher Richard Moyes, Lauren Rogers
  • Patent number: 7329659
    Abstract: The present invention provides a compound of formula (I): in which Ar and R1 are phenyl or a heteroaromatic group, R2 is generally hydrogen, R3 is hydrogen or alkyl and X, Y and Z are generally CH or N as VR-1 antagonists; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising it; its use in therapy; use of it to manufacture medicaments to treat pain or inflammation; and methods of treating pain or inflammation
    Type: Grant
    Filed: April 5, 2004
    Date of Patent: February 12, 2008
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Peter Blurton, Frank Burkamp, Stephen Robert Fletcher, A. Brian Jones, Edward Giles McIver
  • Publication number: 20060235021
    Abstract: A class of 4-phenylpyridazine derivatives of Formula (I), being selective ligands for GABAA receptors, in particular having high affinity for the ?2 and/or ?3 and or ?5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.
    Type: Application
    Filed: August 4, 2003
    Publication date: October 19, 2006
    Inventors: Wesley Blackaby, Peter Blurton, Frank Burkamp, Stephen Fletcher, Andrew Jennings, Richard Lewis, Angus Macleod, Leslie Street, Steve Thomas, Monique Van Niel, Kevin Wilson
  • Publication number: 20060229307
    Abstract: The present invention provides a compound of formula (I): in which Ar and R1 are phenyl or a heteroaromatic group, R2 is generally hydrogen, R3 is hydrogen or alkyl and X, Y and Z are generally CH or N as VR-1 antagonists; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising it; its use in therapy; use of it to manufacture medicaments to treat pain or inflammation; and methods of treating pain or inflammation.
    Type: Application
    Filed: April 5, 2004
    Publication date: October 12, 2006
    Inventors: Peter Blurton, Frank Burkamp, Stephen Fletcher, Brian Jones, Edward Mclver
  • Publication number: 20060040947
    Abstract: the present invention provides a compound of formula (I): wherein V represents NR5, O, S, SO or S(O)2; W and X each independently represent CH or N; Y represents N, CH or C—Ar2, with the proviso that at least one, but no more than two, of W, X and Y are N; Z represents CH or C—Ar2, with the proviso that when Y is N or CH then Z is C—Ar2, and with the further proviso that when Y is C—Ar2 then Z is CH; Ar1 represents a fused 9 or 10 membered heterobicyclic ring system containing one, two, three or four heteroatoms selected from nitrogen, oxygen and sulfur, wherein at least one of the rings in said ring system is aromatic; Ar2 represents an aromatic ring selected from phenyl, pyridyl, pyrimidinyl and pyridazinyl which is optionally fused and substituted; R1 represents halogen, hydroxy, oxo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, hydroxyC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, hydroxyC1-6alkoxy, C3-7cycloalkyl, C3-7cycloalkoxy, C3-5cycloalkylC1-4alkyl, cyano, nitro, SR6, SOR6, SO2R6, COR6, NR3COR6, CON
    Type: Application
    Filed: November 14, 2003
    Publication date: February 23, 2006
    Inventors: Peter Blurton, Frank Burkamp, Sttephen Fletcher, Gregory Hollingworth, A. Brian Jones, edward McIver, Christopher Moyes, Lauren Rogers
  • Patent number: 6936608
    Abstract: A class of 7-phenylimidazo[1,2-b][1,2,4]triazine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group which is directly attached or bridged by an oxygen atom or a —NH— linkage, being selective ligands for GABAA receptors, in particular having good affinity for the ?2 and/or ?3 and/or ?5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.
    Type: Grant
    Filed: November 8, 2001
    Date of Patent: August 30, 2005
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Michela Bettati, Peter Blurton, William Robert Carling, Mark Stuart Chambers, David James Hallett, Andrew Jennings, Richard Thomas Lewis, Michael Geoffrey Neil Russell, Leslie Joseph Street, Helen Jane Szekeres, Monique Bodil Van Neil
  • Patent number: 6777430
    Abstract: A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an N-arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT2A receptor and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of adverse conditions of the central nervous system, including schizophrenia and depression.
    Type: Grant
    Filed: April 1, 2003
    Date of Patent: August 17, 2004
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Peter Blurton, Frank Burkamp, Susan Koon-Fung Cheng, Stephen Robert Fletcher, Angus Murray MacLeod, Daniel Spinks, Monique Bodil Van Niel
  • Publication number: 20040023964
    Abstract: A class of 7-phenylimidazo[1,2-b][1,2,4]triazine derivatives, substituted at the meta position of the phenyl ring by an optionally substituted aryl or heteroaryl group which is directly attached or bridged by an oxygen atom or a —NH— linkage, being selective ligands for GABAA receptors, in particular having good affinity for the &agr;2 and/or &agr;3 and/or &agr;5 subunit thereof, are accordingly of benefit in the treatment and/or prevention of adverse conditions of the central nervous system, including anxiety, convulsions and cognitive disorders.
    Type: Application
    Filed: May 8, 2003
    Publication date: February 5, 2004
    Inventors: Michela Bettati, Peter Blurton, William Robert Carling, Mark Stuart Chambers, David James Hallett, Andrew Jennings, Richard Thomas Lewis, Michael Geoffrey Neil Russell, Leslie Joseph Street, Helen Jane Szekeres, Monique Bodil Van Neil
  • Publication number: 20030203889
    Abstract: A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an N-arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT2A receptor and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of adverse conditions of the central nervous system, including schizophrenia and depression.
    Type: Application
    Filed: April 1, 2003
    Publication date: October 30, 2003
    Applicant: Merck & Co., Inc.
    Inventors: Peter Blurton, Frank Burkamp, Susan Koon-Fung Cheng, Stephen Robert Fletcher, Angus Murray MacLeod, Daniel Spinks, Monique Bodil Van Niel
  • Patent number: 6559166
    Abstract: A class of phenylsulphonyl derivatives wherein the sulphonyl moiety is also attached to an N-arylalkyl-substituted azetidine, pyrrolidine or piperidine ring are selective antagonists of the human 5-HT2A receptor and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of adverse conditions of the central nervous system, including schizophrenia and depression.
    Type: Grant
    Filed: September 27, 2001
    Date of Patent: May 6, 2003
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Peter Blurton, Frank Burkamp, Susan Koon-Fung Cheng, Stephen Robert Fletcher, Angus Murray MacLeod, Daniel Spinks, Monique Bodil Van Niel
  • Patent number: 6180630
    Abstract: Pyrazolo[4,3-c]pyridazin-3-one analogues, represented by are selective ligands for GABAA receptors, in particular having high affinity for the &agr;2 and/or &agr;3 subunit thereof, are useful in the treatment of anxiety and convulsions.
    Type: Grant
    Filed: December 8, 1999
    Date of Patent: January 30, 2001
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Peter Blurton, Stephen Robert Fletcher
  • Patent number: 4988695
    Abstract: Pyrrolo- and dihydropyrrolocinnolines, and their use as inhibitors of gastric acid secretion. A compound of the invention is 1-(2-methylphenyl)-2,3-dihydropyrrolo-[3,2-c]-cinnoline.
    Type: Grant
    Filed: January 23, 1990
    Date of Patent: January 29, 1991
    Assignee: Smith Kline & French Laboratories Limited
    Inventors: Thomas H. Brown, Peter Blurton
  • Patent number: 4732980
    Abstract: This invention relates to intermediates of Mannich-alkynyl aminothiadiazole oxides having histamine H.sub.2 -antagonist activity. A particular final product of this invention is 3-amino-4-[7-piperidinohept-5-ynylamino]-1,2,5-thiadiazole-1-oxide.
    Type: Grant
    Filed: December 8, 1986
    Date of Patent: March 22, 1988
    Assignee: Smith Kline & French Laboratories Limited
    Inventors: Thomas H. Brown, Peter Blurton
  • Patent number: 4663331
    Abstract: This invention relates to Mannich-alkynyl aminothiadiazole oxides having histamine H.sub.2 -antagonist activity. A particular compound of this invention is 3-amino-4-[7-piperidinohept-5-ynylamino]-1,2,5-thiadiazole-1-oxide.
    Type: Grant
    Filed: January 16, 1986
    Date of Patent: May 5, 1987
    Assignee: SmithKline & French Laboratories Limited
    Inventors: Thomas H. Brown, Peter Blurton